CLINICAL PHARMACOLOGY:

In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid, whether given by mouth, stimulates specifically the production of red blood cells, white blood cells, and platelets in persons suffering from certain megaloblastic anemias.

WARNINGS:

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.

PRECAUTIONS:

Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive.

DOSAGE AND ADMINISTRATION:

Oral administration: Folic acid is well absorbed and may be administered orally with satisfactory results except in severe instances of intestinal malabsorption.

Usual therapeutic dosage: Adults and children regardless of age, up to 1.0 mg daily. Resistant cases may require larger doses. Maintenance Level: When clinical symptoms have subsided and the blood picture has become normal, a maintenance level should be used, i.e., 0.1 mg for infants and up to 0.3 mg for children under four years of age, 0.4 mg for adults and children four or more years of age, and 0.8 mg for pregnant and lactating women, per day, but never less than 0.1 mg per day. In the presence of alcoholism, hemolytic anemia, anticonvulsant therapy, or chronic infection, the maintenance level may need to be increased.

How Supplied: Each pack of Ruz-Folic acid 1 or 5 mg tablets contain 100 tablets in 10 blisters.

storage: Store at temperature below 30°C.

Reference: USPDI for Professional Health Care, 2004, Page 1421-4

                  Martindale 2005, Page 1429-31